________________________________________________________
____EntRel____
249
2
____Arg1____
147..247
1
#### Text ####
EPO, or erythropoietin, is a protein the human body makes to stimulate the growth of red blood cells
##############
____Arg2____
249..439
2
#### Text ####
A genetically engineered version of the human protein developed by Amgen Corp. of Thousand Oaks, Calif., recently has been marketed by the Ortho Pharmaceuticals division of Johnson & Johnson
##############
________________________________________________________
________________________________________________________
____Implicit____
441
3
#### Features ####
Wr, Comm, Null, Null
simultaneously, Temporal.Synchrony, Expansion.Conjunction
____Arg1____
249..439
2
#### Text ####
A genetically engineered version of the human protein developed by Amgen Corp. of Thousand Oaks, Calif., recently has been marketed by the Ortho Pharmaceuticals division of Johnson & Johnson
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
441..532
3
#### Text ####
A competing version of EPO is being developed by Genetics Institute Inc. in Cambridge, Mass
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
534
4
____Arg1____
441..532
3
#### Text ####
A competing version of EPO is being developed by Genetics Institute Inc. in Cambridge, Mass
##############
____Arg2____
534..583
4
#### Text ####
The drug is being used primarily to treat anemias
##############
________________________________________________________
________________________________________________________
____Explicit____
862..866
7,1
#### Text ####
then
##############
#### Features ####
Wr, Comm, Null, Null
then, Temporal.Asynchronous.Precedence
____Arg1____
767..855
6
#### Text ####
The patients began receiving EPO injections about a month before their scheduled surgery
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
857..861;867..938
7,0;7,2;7,3
#### Text ####
They began donating blood twice a week, receiving an EPO injection each time
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
940
8
#### Features ####
Wr, Comm, Null, Null
but, Comparison
____Arg1____
857..938
7
#### Text ####
They then began donating blood twice a week, receiving an EPO injection each time
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
940..1004
8
#### Text ####
If tests indicated a low number of red cells, blood wasn't taken
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
940..942
8,0,0
#### Text ####
If
##############
#### Features ####
Wr, Comm, Null, Null
if, Contingency.Condition.General
____Arg1____
986..1004
8,1;8,2;8,3;8,4
#### Text ####
blood wasn't taken
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
943..984
8,0,1
#### Text ####
tests indicated a low number of red cells
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1190
10
#### Features ####
Wr, Comm, Null, Null
and, Expansion.Conjunction
____Arg1____
1008..1188
9
#### Text ####
The EPO-treated patients donated an average of 5.4 units of blood each compared with only 4.1 units donated by a similar group of surgical patients who received a placebo injection
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
1190..1274
10,0
#### Text ####
The volume of red cells donated by the EPO-treated patients was 41% higher per donor
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
